MYP0 Polyclonal Antibody

This gene is specifically expressed in Schwann cells of the peripheral nervous system and encodes a type I transmembrane glycoprotein that is a major structural protein of the peripheral myelin sheath. The encoded protein contains a large hydrophobic extracellular domain and a smaller basic intracellular domain, which are essential for the formation and stabilization of the multilamellar structure of the compact myelin. Mutations in this gene are associated with autosomal dominant form of Charcot-Marie-Tooth disease type 1 (CMT1B) and other polyneuropathies, such as Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN). A recent study showed that two isoforms are produced from the same mRNA by use of alternative in-frame translation termination codons via a stop codon readthrough mechanism.

The MYP0 Polyclonal Antibody is a highly specific and sensitive antibody that has been developed for use in various research applications. This antibody is produced by immunizing animals with a synthetic peptide corresponding to the N-terminal region of the human MYP0 protein. The resulting polyclonal antibody has been purified and characterized to ensure high specificity and sensitivity.

The MYP0 Polyclonal Antibody is suitable for use in a variety of applications, including Western blotting, immunohistochemistry, and immunofluorescence. It has been validated for use in human samples and has been shown to detect endogenous levels of MYP0 protein in various tissues and cell lines.

This antibody is supplied as a liquid in phosphate-buffered saline (PBS) with 0.02% sodium azide as a preservative. It is available in various sizes to meet the needs of different research applications.

Overall, the MYP0 Polyclonal Antibody is a reliable and high-quality tool for researchers studying the MYP0 protein and its role in various biological processes. Its high specificity and sensitivity make it an ideal choice for a wide range of applications.